AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...

The U.S. Food and Drug Administration on Tuesday approved AbbVie Inc.’s (NYSE:ABBV) Rinvoq (upadacitinib), 15 mg, once daily, for giant cell arteritis (GCA). GCA is an inflammation of blood vessels, ...

RINVOQ is approved in the European Union (EU) for the treatment of adults with radiographic axial spondylarthritis, nonradiographic axial spondylarthritis, psoriatic arthritis, rheumatoid arthritis, ...

AbbVie (NYSE: ABBV) recently released its Q4 results, with revenues and earnings comfortably above the street estimates. It reported sales of $15.1 billion and adjusted earnings of $2.16 per share, ...

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from the ...